Literature DB >> 7347568

In vitro susceptibilities of Aeromonas hydrophila to 32 antimicrobial agents.

R J Fass, J Barnishan.   

Abstract

Minimal inhibitory concentrations of 32 antimicrobial agents for 20 strains fo Aeromonas hydrophila were determined by a microdilution method. Moxalactam was the most active drug tested. All strains were also susceptible to clinically achievable concentrations of mecillinam, cefamandole, cefuroxime, cefotaxime, aminoglycosides (except streptomycin), tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7347568      PMCID: PMC181430          DOI: 10.1128/AAC.19.2.357

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Aeromonas hydrophila in clinical bacteriologic specimens.

Authors:  J A Washington
Journal:  Ann Intern Med       Date:  1972-04       Impact factor: 25.391

2.  The genus aeromonas in human bacteriology; report of 30 cases and review of the literature.

Authors:  A Von Graevenitz; A H Mensch
Journal:  N Engl J Med       Date:  1968-02-01       Impact factor: 91.245

3.  Antimicrobial susceptibility of Aeromonas hydrophila.

Authors:  T L Overman
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

4.  In vitro activity of cefoperazone against nonfermenters and Aeromonas hydrophila.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

5.  Antibiotic sensitivity of two Aeromonas and nine Pseudomonas species.

Authors:  C E Nord; T Wadström; B Wretlind
Journal:  Med Microbiol Immunol       Date:  1975       Impact factor: 3.402

  5 in total
  14 in total

1.  Activity of newer antimicrobial agents against Aeromonas hydrophila.

Authors:  K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

2.  In vitro susceptibilities of tropical strains of Aeromonas species from Queensland, Australia, to 22 antimicrobial agents.

Authors:  J M Koehler; L R Ashdown
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

3.  In vitro susceptibilities of Aeromonas hydrophila against new antibiotics.

Authors:  V Fainstein; S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

4.  Antimicrobial susceptibility patterns of Aeromonas jandaei, A. schubertii, A. trota, and A. veronii biotype veronii.

Authors:  T L Overman; J M Janda
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

5.  Unusual case of Aeromonas hydrophila endocarditis.

Authors:  K R Ong; E Sordillo; E Frankel
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

6.  Seasonal incidence of and antibiotic resistance among Aeromonas species isolated from domestic wastewater before and after treatment in stabilization ponds.

Authors:  L Hassani; B Imziln; A Boussaid; M J Gauthier
Journal:  Microb Ecol       Date:  1992-05       Impact factor: 4.552

7.  Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  Clinical and microbiological features of Aeromonas hydrophila-associated diarrhea.

Authors:  W A Agger; J D McCormick; M J Gurwith
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

9.  Isolation of enterotoxigenic, hemolytic, and antibiotic-resistant Aeromonas hydrophila strains from infected fish in Bangladesh.

Authors:  Z Rahim; S C Sanyal; K M Aziz; M I Huq; A A Chowdhury
Journal:  Appl Environ Microbiol       Date:  1984-10       Impact factor: 4.792

10.  Antimicrobial susceptibility of Aeromonas species isolated from patients with diarrhea.

Authors:  V H San Joaquin; R K Scribner; D A Pickett; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.